Annals of Coloproctology

Display

Sort by :

Guideline

Colorectal cancer

The Korean Rectal Cancer Multidisciplinary Committee Clinical Practice Guidelines for Rectal Cancer version 2.0: Hyo Seon Ryu, Hyun Jung Kim, Dong Hyun Kang, Yoo-Kang Kwak, Han Deok Kwak, Yoon-Hye Kwon, Dalyong Kim, Baek-Hui Kim, Jae Hyun Kim, Ji Hun Kim, Jin Won Kim, Tae Hyung Kim, Hae Young Kim, Soo Min Nam, Gyoung Tae Noh, Jun Woo Bong, Nak Song Sung, Seon Hui Shin, Kil-Yong Lee, Sung Chul Lee, Sea-Won Lee, Jung Won Lee, Jong Min Lee, Myung Hoon Ihn, Joo Han Lim, Woong Bae Ji, Dae Hee Pyo, Young Ki Hong, Jung-Myun Kwak, on behalf of the Korean Rectal Cancer Multidisciplinary (KRCM) Committee; Ann Coloproctol. 2026;42(1):4-33. Published online February 24, 2026; DOI: https://doi.org/10.3393/ac.2025.01396.0199

5,566 View
270 Download
1 Web of Science
2 Citations

Rectal cancer, which accounts for approximately 40% of colorectal cancers, remains a major clinical concern. Recent advances in diagnostic imaging, surgical techniques, radiotherapy, and systemic treatment have steadily improved rectal cancer outcomes. Considering this, the Korean Rectal Cancer Multidisciplinary (KRCM) Committee has aimed to provide clinicians and policymakers with up-to-date, evidence-based clinical practice guidelines to support optimal decision-making, reflecting current evidence, the Korean healthcare context, and patient values and preferences. The Clinical Practice Guidelines for Rectal Cancer version 2.0 were developed through multidisciplinary collaboration with related academic societies, building upon and updating the KRCM Clinical Practice Guidelines version 1.0 (titled “Multidisciplinary guidelines for the management of rectal cancer”). These consensus guidelines of the KRCM were established based on a comprehensive literature review, evidence synthesis, with recommendation development guided by the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology, and consideration of applicability in real-world clinical practice under the national health insurance system. Each recommendation has been presented with its strength and level of evidence.

Citations

Citations to this article as recorded by

Advances in Neoadjuvant Therapy for Colorectal Cancer
达练
Advances in Clinical Medicine.2026; 16(05): 2273. CrossRef
Near-complete clinical response after neoadjuvant therapy in rectal cancer: Decision-making between organ preservation and surgery
Thanat Tantinam, Kullawat Bhatanaprabhabhan, Boonchai Ngamsirimas, Pawit Sutharat, Rangsima Thiengthiantham, Nataphon Santrakul, Suwan Sanmee, Ekkarin Supatrakul, Punnawat Chandrachamnong, Suradet Buakhrun
World Journal of Clinical Oncology.2026;[Epub] CrossRef

Original Article

Change in Expression of Survivin Caused by Using Oxaliplatin in HCT116 Colon Cancer Cells: Won Jun Sohn, Jung Won Lee, Dong-Guk Park; J Korean Soc Coloproctol. 2010;26(4):246-253. Published online August 31, 2010; DOI: https://doi.org/10.3393/jksc.2010.26.4.246

5,961 View
43 Download
2 Citations

Abstract PDF

Purpose

Oxaliplatin is a third-generation platinum compound, and it has no nephrotoxicity and has reduced bone marrow toxicity. Cancer cells that are resistant to cisplatin are sensitive to oxaliplatin. Oxaliplatin is used widely for the treatment of colon cancers. Recently, oxaliplatin was reported to inhibit the expression of survivin, which protects cell apoptosis. However, there are no reports on the expressions of survivin variants and the changes in intracellular localization of survivin in cancer cells. We studied the expression of survivin caused by oxaliplatin in HCT116 colon cancer cells, and we observed the localization of survivin in the mitotic phase.

Methods

We treated the HCT116 colon cancer cells with 2.0 µM of oxaliplatin, and we studied the expressions of survivin protein, and survivin mRNA variants, as well as the changes in intracellular localization, by using the Western blot method, RT-PCR, immunocytochemistry, and flowcytometry.

Results

Oxaliplatin inhibits the expression of the survivin protein and survivin mRNA in HCT116 colon cancer cells. The expression of the survivin-2B variants, which have no antiapoptotic activity but control cell mitosis by localization on a microtubule, is reduced continuously 2 days after treatment with oxaliplatin. In immunocytochemistry, expression of survivin in the cytoplasm is reduced and especially is not expressed in microtubules and contractile rings.

Conclusion

One of the mechanisms of oxaliplatin is to inhibit the expression of and to change the localization of survivin. Based on these results, we suggest that changes in the expression of survivin variants and in their localization are two effects of oxaliplatin.

Citations

Citations to this article as recorded by

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial
M Verstraete, A Debucquoy, J Dekervel, J van Pelt, C Verslype, E Devos, G Chiritescu, K Dumon, A D'Hoore, O Gevaert, X Sagaert, E Van Cutsem, K Haustermans
British Journal of Cancer.2015; 112(8): 1314. CrossRef
Antichemosensitizing effect of resveratrol in cotreatment with oxaliplatin in HCT116 colon cancer cell
Dong-Guk Park
Annals of Surgical Treatment and Research.2014; 86(2): 68. CrossRef

First
Prev
Page of 1
Next
Last

Search